The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.
 
Lin-Xiaoxi Ma
No Relationships to Disclose
 
Benlong Yang
No Relationships to Disclose
 
Shanshan Gu
Employment - RemeGen Co., Ltd.
 
Tianyu Ren
Employment - RemeGen Co., Ltd.
 
Dandan Gao
Employment - RemeGen Co., Ltd.
 
Jianmin Fang
Stock and Other Ownership Interests - RemeGen Co., Ltd.
 
Jiong Wu
No Relationships to Disclose